On Friday, Taysha Gene Therapies Inc (NASDAQ: TSHA) was -3.20% drop from the session before settling in for the closing price of $2.81. A 52-week range for TSHA has been $1.05 – $3.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -63.99%. When this article was written, the company’s average yearly earnings per share was at 13.55%. With a float of $223.79 million, this company’s outstanding shares have now reached $261.53 million.
Let’s determine the extent of company efficiency that accounts for 73 employees. In terms of profitability, gross margin is 100.0%, operating margin of -1225.78%, and the pretax margin is -1201.08%.
Taysha Gene Therapies Inc (TSHA) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Taysha Gene Therapies Inc stocks. The insider ownership of Taysha Gene Therapies Inc is 14.43%, while institutional ownership is 65.62%. The most recent insider transaction that took place on May 30 ’25, was worth 2,062,500. In this transaction 10% Owner of this company bought 750,000 shares at a rate of $2.75, taking the stock ownership to the 2,841,704 shares.
Taysha Gene Therapies Inc (TSHA) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -0.09 earnings per share (EPS) during the time that was better than consensus figure (set at -0.1) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.55% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.39% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
You can see what Taysha Gene Therapies Inc (TSHA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 98.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.37 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Looking closely at Taysha Gene Therapies Inc (NASDAQ: TSHA), its last 5-days average volume was 2.0 million, which is a drop from its year-to-date volume of 2.87 million. As of the previous 9 days, the stock’s Stochastic %D was 63.48%.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 76.26%, which indicates a significant increase from 66.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.17 in the past 14 days, which was lower than the 0.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.60, while its 200-day Moving Average is $2.06. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $2.81. Second resistance stands at $2.90. The third major resistance level sits at $2.95. If the price goes on to break the first support level at $2.66, it is likely to go to the next support level at $2.61. Now, if the price goes above the second support level, the third support stands at $2.52.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are 214,662K outstanding shares of the company, which has a market capitalization of 711.36 million. As of now, sales total 8,330 K while income totals -89,300 K. Its latest quarter income was 2,300 K while its last quarter net income were -21,530 K.
